At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
500mcg/25mcg once daily +1 moredrug
Likely dose
500mcg/25mcg once dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD
In Brief
A Phase 2 clinical trial evaluating 500mcg/25mcg once daily and Placebo once daily for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 51 participants across 4 sites.
Detailed Summary
The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartJan 2010
Primary CompletionApr 2010
Study CompletionApr 2010
TodayJul 2026
First PostedDec 25, 2009
Enrollment StartJan 1, 2010
Primary CompletionApr 1, 2010
Study CompletionApr 20, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.5 years ago
Interventions
500mcg/25mcg once dailydrug
GSK573719/GW642444
Placebo once dailydrug
Inactive, excipients only